Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DYRK1B
REST API REST API
Homo sapiens
DYRK1B is differentially expressed in 203 experiments: 95 organism parts: skeletal muscle, cerebellum, ... (93 more);, 147 disease states: normal, acute promyelocytic leukemia, ... (145 more);, 47 cell types 232 cell lines 26 compound treatments and 65 other conditions.
Synonyms MIRK
Orthologs dyrk1b (Danio rerio)   A2VDT2_BOVIN (Bos taurus)   D4A382_RAT (Rattus norvegicus)   ENSCING00000007772 (Ciona intestinalis)   Dyrk1b (Mus musculus)   mnb (Drosophila melanogaster)   DYRK1B (Xenopus laevis)   DYRK1B (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, myoblast fusion, protein tyrosine kinase activity, intracellular membrane-bounded organelle, ATP binding, transcription coactivator activity, nucleus, nucleotide binding, protein serine/threonine kinase activity, protein serine/threonine/tyrosine kinase activity, positive regulation of transcription, DNA-dependent, protein kinase activity, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q9Y463
Search EB-eye ENSG00000105204
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-1577, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (29 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
H2882
1
E-MTAB-62
NA19172
1
E-GEOD-19480
GM10843
1
E-TABM-321
226 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-66, E-GEOD-13909, E-GEOD-13987, E-GEOD-11755, ... (29 experiments)

Factor Value U/D Experiments
stromal cell
3
E-GEOD-10797, E-MEXP-2034, E-GEOD-1460
naive T cell
1
E-GEOD-1460
primary fibroblast
1
E-MEXP-66
undifferentiated cell
1
E-GEOD-21668
mesenchymal stem cell
1
E-GEOD-9894
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
41 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-1869, E-GEOD-1577, ... (42 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
asymptomatic HIV-1 infection
1
E-GEOD-16363
141 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-6462, ... (15 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-TABM-782, E-GEOD-1923
endotoxin
1
E-GEOD-3026
ox-LDL
1
E-GEOD-5741
glutamine
1
E-MEXP-1335
Cxcl12
1
1
E-GEOD-7307
resveratrol
1
E-TABM-782
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-2340

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, E-TABM-321, E-TABM-43, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-16363, E-MEXP-935, ... (25 experiments)

Infection
studied in E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-TABM-43, E-GEOD-4922, E-TABM-147

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM